A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

Next Previous
Trial Profile

A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Brentuximab vedotin
  • Indications Hodgkin's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-204
  • Sponsors Merck Sharp & Dohme

    • Most Recent Events

    • 15 Dec 2017 Planned End Date changed from 19 Dec 2019 to 31 Jul 2020.
    • 15 Dec 2017 Planned primary completion date changed from 28 May 2018 to 30 Dec 2018.
    • 13 Feb 2017 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top